Nanobebe US Inc. v. Mayborn (UK) Limited

District Court, S.D. New York·Decided April 18, 2023·No. 1:21-cv-08444·Unknown

Opinion

UNITED STATES DISTRICT COURT SOUTHERN DISTRICT OF NEW YORK

NANOBEBE US INC., Plaintiff, 21-cv-08444 (JLR) -against- OPINION & ORDER MAYBORN (UK) LIMITED et al., Defendants. JENNIFER L. ROCHON, United States District Judge: Plaintiff Nanobebe US Inc. (“Plaintiff” or “Nanobebe”) brings this action against Mayborn (UK) Limited, Mayborn USA, Inc., and Mayborn Group Limited (collectively, “Defendants” or “Mayborn”) seeking a declaratory judgment that Nanobebe is not infringing on Mayborn’s utility patent, U.S. Patent No. 10,952,930 B2 (the “‘930 Patent”). See generally ECF Nos. 1 (“Compl.”), 25-1 (‘930 Patent). Mayborn responded with two counterclaims alleging that Nanobebe is infringing two of its utility patents, the ‘930 Patent and U.S. Patent No. 11,207,244 B2 (the “‘244 Patent”). See generally ECF Nos. 25 (“Answer & Counterclaims”), 25-2 (‘244 Patent). In connection with these competing claims, the parties have asked the Court to construe the disputed terms of the patents at issue. After a technology tutorial on January 18, 2023, the Court held an approximately seven-hour Markman hearing on February 22, 2023. See generally Markman v. Westview Instruments, Inc., 517 U.S. 370 (1996). The parties presented arguments and admitted evidence, but, at their election, did not offer live witness testimony. The Court’s constructions of the disputed terms are set forth below. I. BACKGROUND

A. Factual Background

There are two Mayborn patents at issue in this case – the ‘930 Patent and the ‘244 Patent. ECF Nos. 25-1, 25-2. Both patents concern baby bottles with flexible nipple regions. Id. According to Mayborn, “the patents-in-suit claim a nipple/collar arrangement that more closely mimics the human breast, better controls and defines nipple flexing to prevent flow blockage from nipple collapse, and improves the air vent structure and arrangement so as to more predictably and reliably reduce the risk of colic.” ECF No. 48 (“Mayborn Claim Br.”) at 1. The parties initially disputed 16 of the claim terms from the ‘930 and ‘244 Patents. See ECF No. 45 (“Am. Joint Claim Terms Chart”). As set forth below, the scope of the parties’ disagreement narrowed over the course of this litigation. At the Markman hearing, the parties requested construction of only 10 terms. See infra at n.2. B. Procedural History

Nanobebe filed the Complaint on October 13, 2021. Compl. Mayborn answered and filed two counterclaims on January 13, 2022. Answer & Counterclaims. Nanobebe responded to the counterclaims on February 3, 2022. ECF No. 33. The parties filed an amended joint claim terms chart on August 24, 2022. Am. Joint Claim Terms Chart. Mayborn filed its Claim Construction Statement on September 6, 2022. Mayborn Claim Br. The case was assigned to the undersigned on September 19, 2022. Nanobebe filed its brief responding to Mayborn’s Claim Construction Statement on November 15, 2022. ECF No. 62 (“Nanobebe Claim Br.”). Mayborn filed its reply brief on November 30, 2022. ECF No. 63 (“Mayborn Reply”). The Court held a technology tutorial on January 18, 2023. See ECF No. 69 (“Tech. Tutorial Tr.”). On February 22, 2023, the Court held a Markman hearing. See ECF No. 79 (“Markman Tr.”). Following the Markman hearing, the parties submitted a joint letter addressing questions the Court raised during the hearing. ECF No. 76 (“Joint Letter”).1 II. LEGAL STANDARD

“It is a bedrock principle of patent law that the claims of a patent define the invention to which the patentee is entitled the right to exclude.” Phillips v. AWH Corp., 415 F.3d 1303, 1312 (Fed. Cir. 2005) (en banc) (internal quotation marks and citation omitted). When parties dispute the terms of a patent claim, the court partakes in claim construction, an exercise that “falls exclusively within the province of the court, not . . . the jury.” Teva Pharms. USA, Inc. v. Sandoz, Inc., 574 U.S. 318, 325 (2015) (internal quotation marks and citation omitted). “[T]he construction of claims is simply a way of elaborating the normally terse claim language[] in order to understand and explain, but not to change, the scope of the claims.” Embrex, Inc. v. Serv. Eng’g Corp., 216 F.3d 1343, 1347 (Fed. Cir. 2000) (internal citation omitted). Courts consider two forms of evidence to determine the meaning of claim terms. First, courts consider “intrinsic evidence of record, i.e., the patent itself, including the claims, the specification and, if in evidence, the prosecution history.” Vitronics Corp. v. Conceptronic, Inc.,

90 F.3d 1576, 1582 (Fed. Cir. 1996); see also Phillips, 415 F.3d at 1317 (“The prosecution history, which we have designated as part of the ‘intrinsic evidence,’ consists of the complete record of the proceedings before the PTO and includes the prior art cited during the examination of the patent.” (internal citation omitted)). “[I]ntrinsic evidence is the most significant source of the legally operative meaning of disputed claim language.” Vitronics Corp., 90 F.3d at 1582. As the claims are part of a “fully integrated written instrument,” the specifications are a critical piece of intrinsic evidence. Markman v. Westview Instruments, Inc., 52 F.3d 967, 978

1 The Court will not consider the additional letter Mayborn filed (ECF No. 77) as it is not responsive to the specific questions that the Court asked at the Markman hearing. (Fed. Cir. 1995). The Federal Circuit has held that “the specification ‘is always highly relevant to the claim construction analysis. Usually, it is dispositive; it is the single best guide to the meaning of a disputed term.’” Phillips, 415 F.3d at 1315 (quoting Vitronics, 90 F.3d at 1582). However, the claims, not the specifications, define the scope of the invention such that a court should not read limitations from the specification into the claim. Phillips, 415 F.3d at 1323. For example, where specifications describe specific embodiments of the invention, the claim should

not be confined to those embodiments. Id. When intrinsic evidence leaves ambiguity as to the meaning of the claim terms, a court may rely on extrinsic evidence: that is, “all evidence external to the patent and prosecution history, including expert and inventor testimony, dictionaries, and learned treatises.” Id. at 1317 (quoting Markman, 52 F.3d at 980). However, extrinsic evidence “is generally of less significance than the intrinsic record” and “may not be used ‘to contradict claim meaning that is unambiguous in light of the intrinsic evidence.’” Profectus Tech. LLC v. Huawei Techs. Co., 823 F.3d 1375, 1380 (Fed. Cir. 2016) (quoting Phillips, 415 F.3d at 1324). During claim construction, terms “‘are generally given their ordinary and customary meaning,’ which is ‘the meaning that the term would have to a person of ordinary skill in the art

[“POSITA”] in question at the time of the invention.’” Network-1 Techs., Inc. v. Hewlett- Packard Co., 981 F.3d 1015, 1022 (Fed. Cir. 2020) (quoting Phillips, 415 F.3d at 1312-13). “In some cases, the ordinary meaning of claim language as understood by a person of skill in the art may be readily apparent even to lay judges, and claim construction in such cases involves little more than the application of the widely accepted meaning of commonly understood words.” Phillips, 415 F.3d at 1314. III. DISPUTED TERMS IN THE UTILITY PATENTS

Free access — add to your briefcase to read the full text and ask questions with AI

Nanobebe US Inc. v. Mayborn (UK) Limited, (S.D.N.Y. 2023).

Nanobebe US Inc. v. Mayborn (UK) Limited (Nanobebe US Inc. v. Mayborn (UK) Limited) — published by Counsel Stack Legal Research, free access to 12M+ legal documents.

Related

Kara Technology Inc. v. stamps.com Inc.
582 F.3d 1341 (Federal Circuit, 2009)
Boss Industries, Inc. v. Yamaha Motor Corp., U.S.A., Inc.
333 F. App'x 531 (Federal Circuit, 2009)
Curtiss-Wright Flow Control, Corp. v. Velan, Inc.
438 F.3d 1374 (Federal Circuit, 2006)
Invitrogen Corp. v. Biocrest Manufacturing, l.p.
424 F.3d 1374 (Federal Circuit, 2005)
Free Motion Fitness, Inc. v. Cybex International, Inc.
423 F.3d 1343 (Federal Circuit, 2005)
Becton Dickinson and Company v. C.R. Bard, Inc.
922 F.2d 792 (Federal Circuit, 1990)
Vitronics Corporation v. Conceptronic, Inc.
90 F.3d 1576 (Federal Circuit, 1996)
John D. Watts v. Xl Systems, Inc.
232 F.3d 877 (Federal Circuit, 2000)
Altiris, Inc. v. Symantec Corp., Defendant-Cross
318 F.3d 1363 (Federal Circuit, 2003)
Chef America, Inc. v. Lamb-Weston, Inc.
358 F.3d 1371 (Federal Circuit, 2004)
Nautilus, Inc. v. Biosig Instruments, Inc.
134 S. Ct. 2120 (Supreme Court, 2014)